✦ LIBER ✦

Drug policy for visceral leishmaniasis: a cost-effectiveness analysis

✍ Scribed by V. Vanlerberghe; G. Diap; P. J. Guerin; F. Meheus; S. Gerstl; P. Van der Stuyft; M. Boelaert

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness projections of single

✍ Piero Olliaro; Sarah Darley; Ramanan Laxminarayan; Shyam Sundar 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 108 KB

Anthropometrically derived dosing and dr

✍ P. Olliaro; S. Sundar 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 100 KB

Endogenous IL-4 is necessary for effecti

✍ James Alexander; K. Christine Carter; Nuri Al-Fasi; Abhay Satoskar; Frank Bromba 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB

A cost-effective cure for cutaneous leis

✍ Karina Corware; Matthew Rogers; Ian Teo; Naresh Kikkeri; Ingrid Müller; Sunil Sh 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Testing for BRCA1 mutations: a cost-effe

✍ Sevilla, Christine; Moatti, Jean-Paul; Julian-Reynier, Claire; Eisinger, Françoi 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 115 KB

Spiraling Drug Costs: A Call for Cost-Ef

✍ Chester B. Good 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB